SeaStar Medical Hyperinflammation Therapy 2023 Investor Presentation

SeaStar Medical is developing the Selective Cytopheretic Device (SCD), an extracorporeal cell-directed therapy designed to address life-threatening hyperinflammation by neutralizing activated immune cells and restoring homeostasis. The company went public via SPAC merger in October 2022 and is advancing the SCD platform for treating acute kidney injury and other hyperinflammatory conditions.